Automate Your Wheel Strategy on LTRN
With Tiblio's Option Bot, you can configure your own wheel strategy including LTRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LTRN
- Rev/Share 0.0
- Book/Share 1.5556
- PB 1.9607
- Debt/Equity 0.0116
- CurrentRatio 4.858
- ROIC -1.2526
- MktCap 32893335.0
- FreeCF/Share -1.774
- PFCF -1.7193
- PE -1.6548
- Debt/Assets 0.0092
- DivYield 0
- ROE -0.8326
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operator Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
Read More
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve.
Read More
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Read More
About Lantern Pharma Inc. (LTRN)
- IPO Date 2020-06-11
- Website https://www.lanternpharma.com
- Industry Biotechnology
- CEO Mr. Panna Sharma
- Employees 24